ATAI Investor Presentation Deck

Depression positioning and landscape: atai's programs are designed to be differentiated from one another and from competitors Company Compound Potential for at home use Potential for sustained efficacy Rapid onset of treatment effect¹ Mechanism of Action In-clinic duration Distribution channels TRD treatments being developed by atai companies Compass COMP360 (₁) (~) 5-HT2A-R agonist 6-8 hours New clinic infrastructure Viridia VLS-01 (✓) 5-HT2A-R agonist -2 hours S-ketamine + New clinic infrastructure Perception PCN-101 (₁) (~) ( Glutamatergic modulator ~2 hours S-ketamine + New clinic infrastructure J&J S-ketamine (₁) NMDA-R antagonist ~2 hours S-ketamine clinics Marketed therapies e.g. Lilly, Pfizer SSRI/SNRI O SERT/NET blockade N/A Pharmacies Axsome Auvelity (~) (✓) () NMDA-R antagonist N/A Pharmacies Various MIJ-821, NRX- 102, JNJ-5515 (Ⓒ) tbd tbd Phase II and III competitors NMDA-R/ mGluR2 antagonists tbd tbd GH Research 5-MeO-DMT 5-HT1A- and 5-HT2A- agonist tbd tbd Note: 5HT2A-R = Serotonin 2A receptor, KOR= kappa-opioid receptor, NMDA-R = N-methyl-D-aspartate receptor, NET = Norepinephrine transporter, SERT = Serotonin Transporter, mGluR2 = Metabotropic glutamate receptor 2, GABA = Gamma-aminobutyric acid, DMT = Dimethyltryptamine, 5-MeO-DMT = 5-methoxy-N,N-dimethyltryptamine, SSRI = Selective Serotonin Reuptake Inhibitor, SNRI = Selective serotonin-norepinephrine reuptake Inhibitor., COMP360 = a proprietary high-purity, polymorphic crystalline formulation of psilocybin; In COMPASS's model of psilocybin therapy, COMP360 is administered in conjunction with psychological support from specially trained therapists. Sources: GlobalData, Evaluate Pharma (both as of 2021), Uthaug, M. V. et al. Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology 237,773-785 (2019). company websites (1) Rapid onset of treatment effect versus standard of care 18 Sage / Praxis SAGE-217, PRAX-114 (~) tbd GABAA positive allosteric modulator tbd tbd

View entire presentation